HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAART-associated lipodystrophy

Antiviral Therapy

Volumn 11, Issue 6, 2006, Pages 729-740

  Giralt, Marta ^a   Domingo, Pere ^b   Guallar, Jordi P ^a   Rodríguez De La Concepción, M Luísa ^a   Alegre, Marta ^b   Domingo, Joan C ^a   Villarroya, Francesc ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADIPOCYTOKINE; ADIPONECTIN; CYTOCHROME C OXIDASE; DIDANOSINE; EFAVIRENZ; FIBRINOGEN; INDINAVIR; LAMIVUDINE; LEPTIN; LOPINAVIR PLUS RITONAVIR; MESSENGER RNA; MITOCHONDRIAL PROTEIN; NEVIRAPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RITONAVIR; STAVUDINE; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN 3; ZIDOVUDINE;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; ADULT; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIPODYSTROPHY; MALE; MITOCHONDRION; PRIORITY JOURNAL; SUBCUTANEOUS TISSUE; UPREGULATION;

ADIPOCYTES; ADIPOSE TISSUE; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; GENE EXPRESSION REGULATION; HIV INFECTIONS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; MITOCHONDRIA; PROTEINS; SUBCUTANEOUS TISSUE;

EID: 33749366275     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
2. Chen D, Misra A, Garg A. Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 2002; 87:4845-4856.
3. Miller J, Carr A, Emery S, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med 2003; 4:293-301.
4. Nolan D, John M, Mallal S. Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis. Antivir Ther 2001; 6:145-160.
5. Johnson JA, Albu JB, Engelson ES, et al. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab 2004; 286:E261-E271.
6. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89:2548-2556.
7. Domingo P, Matias-Guiu X, Pujol RM, et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 1999; 13:2261-2267.
8. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17:1329-1338.
9. Jan V, Cervera P, Maachi M, et al. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther 2004; 9:555-564.
10. Domingo P, Matias-Guiu X, Pujol RM, et al. Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy. J Infect Dis 2001; 184:1197-1201.
11. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354:1112-1115.
12. Pace CS, Martin AM, Hammond EL, Mamotte CD, Nolan DA, Mallal SA. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther 2003; 8:323-331.
13. Caron M, Auclair M, Lagathu C, et al. The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS 2004; 18:2127-2136.
14. Rodriguez de la Concepcion ML, Yubero P, Domingo JC, et al. Reverse transcriptase inhibitors alter uncoupling protein-1 and mitochondrial biogenesis in brown adipocytes. Antivir Ther 2005; 10:515-526.
15. Gougeon ML, Penicaud L, Fromenty B, Leclercq P, Viard JP, Capeau J. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir Ther 2004; 9:161-177.
16. Lagathu C, Bastard JP, Auclair M, et al. Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro. Antivir Ther 2004; 9:911-20.
17. Bastard JP, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359:1026-31.
18. Kannisto K, Sutinen J, Korsheninnikova E, et al. Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS 2003; 17:1753-1762.
19. Sutinen J, Korsheninnikova E, Funahashi T, Matsuzawa Y, Nyman T, Yki-Jarvinen H. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J Clin Endocrinol Metab 2003; 88:1907-1910.
20. Lihn AS, Richelsen B, Pedersen SB, et al. Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab 2003; 285:E1072-E1080.
21. Christeff N, Melchior JC, de Truchis P, Perronne C, Nunez EA, Gougeon ML. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS 1999; 13:2251-2260.
22. Fontdevila J, Martinez E, Rubio-Murillo JM, Milinkovic A, Serra-Renom JM, Gatell JM. A practical classification for the surgical filling of facial lipoatrophy. Antivir Ther 2005; 10 Suppl 3:L28.
23. Lemieux S, Prud'homme D, Bouchard C, Tremblay A, Despres JP. A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr 1996; 64:685-693.
24. Centers for Disease Control 1987 Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Recomm Rep 36 Suppl:3S-14S
25. Sun R, Ku J, Jayakar H, et al. Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1998; 36:2964-2969
26. Rodriguez de la Concepcion ML, Guallar JP, Yubero P, et al. Role of disturbances of brown with respect to white adipocyte biology in HAART-associated lipodystrophy and lipomatosis: studies in vitro and in vivo. Antivir Ther 2005; 10 Suppl 3:L19.
27. Rodriguez de la Concepcion ML, Domingo JC, Domingo P, Giralt M, Villarroya F. Uncoupling protein 1 gene expression implicates brown adipocytes in highly active antiretroviral therapy-associated lipomatosis. AIDS 2004; 18:959-960.
28. Kelly DP, Scarpulla RC. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev 2004; 18:357-368.
29. Gobin SJ, Biesta P, Van den Elsen PJ. Regulation of human beta 2microglobulin transactivation in hematopoietic cells. Blood 2003; 101:3058-3064.
30. Villarroya F, Domingo P, Giralt M. Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. Trends Biochem Sci 2005; 26:88-93.
31. Galluzzi L, Pinti M, Guaraldi G, et al. Altered mitochondrial RNA production in adipocytes from HIV-infected individuals with lipodystrophy. Antivir Ther 2005;10 Suppl 2:M91-M99.
32. Miro O, Lopez S, Martinez E, et al. Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals. Clin Infect Dis 2004; 39:710-716.
33. Casula M, Bosboom-Dobbelaer I, Smolders K, et al. Infection with HIV-1 induces a decrease in mtDNA. J Infect Dis 2005; 191:1468-71.
34. Lopez S, Garrabou G, Martinez E, et al. Mitochondrial studies in adipose tissue of HIV-infected patients without fat redistribution. Antivir Ther 2004; 9:L20.
35. Nolan D, Hammond E, James I, McKinnon E, Mallal S. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 2003; 8:617-626.
36. Hammond E, Nolan D, McKinnon E, Pace C, Metcalf C, Mallal S. Assessing the contribution of ART, HIV and host factors to adipose tissue changes occurring in HIV-infected individuals: risk profile for lipoatrophy. Antivir Ther 2005; 10:L4.
37. Nerurkar PV, Shikuma CM, Nerurkar VR. Sterol regulatory element-binding proteins and reactive oxygen species: potential role in highly-active antiretroviral therapy (HAART)-associated lipodystrophy. Clin Biochem 2001; 34:519-529.
38. Rousset S, Alves-Guerra MC, Mozo J, et al. The biology of mitochondrial uncoupling proteins. Diabetes 2004; 53 Suppl 1:S130-S135.
39. Boss O, Bobbioni-Harsch E, Assimacopoulos-Jeannet F, et al. Uncoupling protein-3 expression in skeletal muscle and free fatty acids in obesity. Lancet 1998; 351:1933.
40. Spiegelman BM, Choy L, Hotamisligil GS, Graves RA, Tontonoz P. Regulation of adipocyte gene expression in differentiation and syndromes of obesity/diabetes. J Biol Chem 1993; 268:6823-6826.
41. Viguerie N, Vidal H, Arner P, et al. Adipose tissue gene expression in obese subjects during low-fat and high-fat hypocaloric diets. Diabetologia 2005; 48:123-131.
42. Mondal D, Larussa VF, Agrawal KC. Synergistic antiadipogenic effects of HIV type 1 protease inhibitors with tumor necrosis factor alpha: suppression of extracellular insulin action mediated by extracellular matrix-degrading proteases. AIDS Res Hum Retroviruses 2001; 17:1569-1584.
43. Villena JA, Kim KH, Sul HS. Pref-1 and ADSF/resistin: two secreted factors inhibiting adipose tissue development. Horm Metab Res 2002; 34:664-670.
44. Xie J, Yi Q. Beta2-microglobulin as a potential initiator of inflammatory responses. Trends Immunol 2003; 24:228-229.
45. Ledru E, Christeff N, Patey O, de Truchis P, Melchior JC, Gougeon ML. Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 2000; 95:3191-3198.
46. Warne JP. Tumour necrosis factor alpha: a key regulator of adipose tissue mass. J Endocrinol 2003; 177:351-355.
47. Puigserver P, Rhee J, Lin J, et al. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. Mol Cell 2001; 8:971-982.
48. Chi D, Henry J, Kelley J, Thorpe R, Smith JK, Krishnaswamy G. The effects of HIV infection on endothelial function. Endothelium 2000; 7:223-242.
49. Maurin T, Saillan-Barreau C, Cousin B, Casteilla L, Doglio A, Pénicaud L. Tumor necrosis factor-a stimulates HIV-1 production in primary culture of human adipocytes. Exp Cell Res 2005; 304:544-551.
50. Kino T, Chrousos GP. Human immunodeficiency virus type-1 accessory protein Vpr: a causative agent of the AIDS-related insulin resistance/ lipodystrophy syndrome? Ann N Y Acad Sci 2004; 1924:153-167
51. Garg A. Acquired and inherited lipodystrophies. N Engl J Med 2004; 350:1220-1234.
52. Reitman ML, Arioglu E, Gavrilova O, Taylor SI. Lipoatrophy revisited. Trends Endocrinol Metab 2000; 11:410-416.
53. Neschen S, Morino K, Rossbacher JC, et al. Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice. Diabetes 2006; 55:924-28.
54. Mynarcik DC, Combs T, McNurlan MA, Scherer PE, Komaroff E, Gelato MC. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J Acquir Immune Defic Syndr 2002; 31:514-520.
55. Kosmiski L, Kuritzkes D, Lichtenstein K, Eckel R. Adipocyte-derived hormone levels in HIV lipodystrophy. Antivir Ther 2003; 8:9-15.
56. Tong Q, Sankale JL, Hadigan CM, et al. Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. J Clin Endocrinol Metab 2003; 88:1559-1564.
57. Vigouroux C, Maachi M, Nguyen TH, et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003; 17:1503-1511.
58. Lindegaard B, Keller P, Bruunsgaard H, Gerstoft J, Pedersen BK. Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients. Clin Exp Immunol 2004; 135:273-279.
59. Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004; 363:429-438
60. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med 2004; 140:786-794.
61. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351:1106-1118.